Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine plus Penpulimab in advanced ESCC
NCT05265962Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of decitabine and penpulimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Overall Survival at 24 months. Status: unknown.
02
Drugs
decitabinepenpulimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05265962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265962.